Cargando…
Clinical outcomes in elderly patients with Morquio a syndrome receiving enzyme replacement therapy - experience in a Colombian center
INTRODUCTION: Mucopolysaccharidosis type IV A (MPS IVA) or Morquio A syndrome is an autosomal recessive lysosomal storage disease caused by GALNS gene mutations that lead to a deficiency of the N-acetylgalactosamine-6-sulfate sulfatase enzyme and the accumulation of two glycosaminoglycans in cell ly...
Autores principales: | Erazo-Narváez, Andrés Felipe, Muñoz-Vidal, Juan Manuel, Rodríguez-Vélez, Guillermo Hernando, Acosta-Aragón, María Amparo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718482/ https://www.ncbi.nlm.nih.gov/pubmed/33304816 http://dx.doi.org/10.1016/j.ymgmr.2020.100679 |
Ejemplares similares
-
Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome
por: Tomatsu, Shunji, et al.
Publicado: (2015) -
Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome
por: Qi, Yulan, et al.
Publicado: (2014) -
Morquio A syndrome and effect of enzyme replacement therapy in different age groups of Turkish patients: a case series
por: Kılavuz, Sebile, et al.
Publicado: (2021) -
30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: About one case
por: Do Cao, J., et al.
Publicado: (2016) -
Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management
por: Solanki, Guirish A., et al.
Publicado: (2013)